Inclusion Criteria:

- Part 1: Histologically or cytologically confirmed, locally advanced or metastatic,
treatment-refractory solid tumors

- Part 2: Histologically or cytologically confirmed, locally advanced or metastatic:
NSCLC (squamous or non-squamous cell carcinoma; up to 2 prior treatment regimens),
Colorectal Cancer (up to 2 prior treatment regimens), Pancreatic Cancer (up to 1
prior treatment regimen), Ovarian cancer (up to 2 prior treatment regimens), or
Sarcoma (up to 2 prior treatment regimens), according to cohort availability

- Eastern Cooperative Group (ECOG performance status of 0 or 1

- Women or men ≥16 years of age

- Adequate hematology, renal, hepatic, coagulation and glycemic function.

Exclusion Criteria:

- Presence of uncontrolled central nervous system (CNS) disease

- Systemic chemotherapy, hormonal therapy, immunotherapy, experimental or approved
anticancer proteins/antibodies therapy ≤28 days before enrollment.

- Prior treatment with death receptor agonists (including but not limited to
rhApo2L/TRAIL [AMG951], apomab, mapatumumab, lexatumumab, CS-1008)

- Prior treatment with IGF receptor antagonists (including but not limited to CP-751,
871, MK0646, AVE1642 or IMC-A12)